跳至主要内容
临床试验/NCT04957329
NCT04957329招募中4 期

Department of Ophthalmology, Rigshospitalet-Glostrup Valdemar Hansens Vej 13, 2600 Glostrup, Denmark

Rigshospitalet, Denmark2 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2021年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
入组人数
28
试验地点
2
主要终点
Goblet cell density

研究概览

简要总结

a randomized, investigator-blind, interventinal study will compare the effect of benzalkonium-chloride (BAK) preserved and preservative-free (PF) eye drops on conjunctival goblet cells.

详细描述

The investigators will conduct a randomized, investigator-blind, interventinal study on 28 subjects. Each subject will apply a benzalkonium-chloride (BAK) preserved eye drop (Xalatan) in one eye and a preservative-free (PF) eye drop (Monoprost) in the other for 3 months. Which eye gets which treatment is randomized. Before and after treatment a conjunctival print will be made and the effect of the eye drops on goblet cell density will be evaluated along with effect on the intraocular pressure.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18years
  • Danish speaking
  • Open angle glaucoma or ocular hypertension
  • Average intraocular pressure equal to or above 22 mmHg

排除标准

  • a. history of significant eye diseae (including okular trauma) other than open angle glaucoma and ocular hypertension d. treatment with steroids within the last 3 months from inclusion e. Significant untreated systemic disease such as hypertension, heart failure, diabetes mellitus, stroke, lung disease and autoimmune diseases. Diseases are not reason for exclusion if they are well treated or does not need treatment g. pregnant or breast feeding h. women using unsafe anticonception i. allergy towards trial medication j. patients who cannot cooperate in eye examination k. ocular surface defects l. need for polytherapy in glaucoma treatment

研究组 & 干预措施

BAK-preserved

Active Comparator

Xalatan eye drop

干预措施: Xalatan (Drug)

Preservative-free

Active Comparator

Monoprost eye drop

干预措施: Monoprost (Drug)

结局指标

主要结局

Goblet cell density

时间窗: 3 months

Change in goblet cell density

次要结局

  • Ocular surface disease index evaluation(3 months)
  • Intraocular pressure(3 months)
  • Cytokines in tear film(3 months)
  • Ocular surface(3 months)
  • Mucin content in tear film(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anne Hedengran Nagstrup

Department of ophthalmology

Rigshospitalet, Denmark

研究点 (2)

Loading locations...

相似试验